

Review/Meta-analysis

Cite this article: Wong WLE, Sually D, Hidalgo-Mazzei D, Quidbach V, Simon J, Boyer P, Strawbridge R, Young AH (2023). The effects of COVID-19 on European healthcare provision for working-age adults with major depressive disorder. *European Psychiatry*, 66(1), e39, 1–11
<https://doi.org/10.1192/j.eurpsy.2023.2407>

Received: 11 November 2022

Revised: 20 February 2023

Accepted: 26 February 2023

Keywords:









Care pathways; COVID-19; major depressive disorder; pandemic

Corresponding author:

Rebecca Strawbridge;
 Email: Becci.strawbridge@kcl.ac.uk

A.H.Y and R.S. contributed equally as senior authors.

The effects of COVID-19 on European healthcare provision for working-age adults with major depressive disorder

Win Lee Edwin Wong^{1,2} , Dilveer Sually² , Diego Hidalgo-Mazzei^{2,3} , Vinciane Quidbach⁴ , Judit Simon⁵ , Patrice Boyer⁴ , Rebecca Strawbridge²  and Allan H. Young² 

¹Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; ²Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK; ³Bipolar and Depressive Disorders Unit, Department of Psychiatry and Psychology, Institute of Neuroscience, Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; ⁴European Brain Council, Brussels, Belgium and ⁵Department of Health Economics, Center for Public Health, Medical University of Vienna, Vienna, Austria

Abstract

Background. Major depressive disorder (MDD) is a leading cause of disability worldwide, and yet delivery of care for this illness is rife with gaps. The COVID-19 pandemic has had far reaching implications for every facet of healthcare, and MDD is no exception. This scoping review aimed to ascertain the impacts of COVID-19 on the delivery of MDD care in Europe, as well as to evaluate any novel MDD care strategies trialled in this period.

Methods. We searched the PubMed and PsycINFO databases up to January 2022 with a strategy centred around COVID-19 and MDD. Full texts of eligible studies examining working-age adults and conducted in Europe were evaluated against several criteria. All outcomes were then extracted and a narrative synthesis was constructed to summarise identified themes.

Results. Of 1,744 records identified in our search, 11 articles were eligible for inclusion in the review. In general, these studies reported a decrease in treatment rates, access to care, and perceived access to care during the COVID-19 pandemic. In addition, digital interventions trialled during the pandemic were broadly well-received by users, though their efficacy in improving MDD care was ambiguous.

Conclusions. Despite a limited number of pertinent studies, this scoping review identified a trend of exacerbated treatment gaps in MDD care during the pandemic. Several of our pre-specified gaps, including delays to detection or treatment of depression and rates of follow-up contacts, remained unexplored in the context of COVID-19. This highlights the need for further investigation to obtain a full understanding of the relationship between COVID-19 and MDD care in Europe.

Introduction

Major depressive disorder (MDD) is one of the most common psychiatric disorders, with the World Health Organisation reporting that over 300 million people globally live with MDD, making this illness the leading cause of disability worldwide [1]. This manifests in enormous burdens on society, both in its direct effects on quality of life and productivity, as well as in its effects on healthcare services and various facets of the economy. Given its prevalence and impact, there has been much focus on improving treatment outcomes for MDD, culminating in a wide variety of well-established treatment guidelines that span primarily pharmacological and psychological interventions [2, 3]. Despite this, existing MDD care is suboptimal, which is no surprise given the complex pathogenesis, diagnostic heterogeneity, and high comorbidity associated with MDD [4–6]. Given these issues, it is no surprise that there is increasing focus on strategies to improve the management and care of MDD [7–9].

Our previous investigation of existing inefficiencies across the MDD care pathway revealed substantial treatment gaps in Europe and identified several recommendations to enhance MDD management [10]. In summary, it was evident from this care pathway analysis that a large proportion of people who meet the criteria for MDD across Europe are not recognised by healthcare providers, are not accessing recommended first-line treatments, are not adequately followed up after initiating treatment, and are not able to access specialist or secondary care. There are many factors that perpetuate the prevalence of these treatment gaps, from patient-centric psychosocial circumstances to broader inefficiencies in implementation of government policy [11–13]. Using a modified-Delphi method (a systematic and iterative approach to reaching consensus views among experts when experimental methodology is not suitable),

© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association. This is an Open Access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives licence (<http://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided that no alterations are made and the original article is properly cited. The written permission of Cambridge University Press must be obtained prior to any commercial use and/or adaptation of the article.



several recommendations were generated, pertaining to improving diagnosis, optimising provision of treatment, and prioritising continuity of care. However, even if some of the recommendations could be successfully implemented, it is difficult to predict with accuracy how the MDD care landscape will change in the near future.

This uncertainty has become exacerbated with the emergence of the COVID-19 pandemic since the completion of our initial care pathway analysis. COVID-19 has exerted major impacts across systems globally, affecting overall healthcare utilisation and disease care as tremendous resources were re-allocated to COVID-19 management [14, 15]. The pandemic thus has clearly affected mental healthcare, though the extent and nature of these impacts are not immediately obvious, given care pathways in mental health are especially complex and multifaceted [16, 17]. It is clear that the COVID-19 pandemic has worsened existing health inequalities and increased the rates of several neuropsychiatric conditions [18, 19]. However, it has simultaneously been suggested that the pandemic offers society an opportunity to re-design the fragmented care systems in place, shifting it towards a more patient-centric system with more inbuilt resilience [20, 21].

This study is part of a larger European Brain Council value of treatment study, which aims to improve service provision for several neuropsychiatric conditions (including MDD) across Europe. Given the extensive influence of COVID-19, the recommendations stemming from this overarching study would hold suboptimal value without an understanding of how the pandemic has affected existing MDD care pathways. Therefore, in this scoping review, we aim to evaluate the effects of COVID-19 on pre-specified treatment gaps in MDD (detailed in our previous work) and to identify any strategies implemented to mitigate pandemic-related disruptions to MDD care.

Methods

This scoping review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for scoping reviews (PRISMA-ScR) statement, which was developed to standardise the heterogeneous methodology amongst existing scoping reviews [22]. This statement comprises a 22-item checklist developed by a panel of experts adhering to the Enhancing the QUALity and Transparency Of health Research (EQUATOR) Network recommendations. A protocol for this scoping review was written prior to the searches being undertaken and published in MedRxiv following the searches [23].

Search strategy

An electronic search of the PubMed and PsycINFO (via OVID) databases was conducted on 28 January 2022, for publications after 1 January 2020, a cut-off corresponding to the arrival of COVID-19 in Europe. Search strings relevant to MDD and COVID-19 were interrogated within all fields in PubMed, including record titles and abstracts, using the following search strategy: ((COVID-19 or COVID 2019 or severe acute respiratory syndrome coronavirus 2 or 2019 nCoV or SARS-COV2 or 2019nCoV or novel coronavirus) and (major depression or major depressive disorder or major depressive episode or MDD or MDE)). The search strategy was adapted for PsycINFO accordingly. The reference lists of articles yielded in the electronic search were also hand-searched to identify additional articles that possibly fit eligibility criteria.

Screening and eligibility criteria

Each study identified during database searching was imported into EndNote reference manager software for (automated and then manual) duplicate removal. W.L.E.W. and D.S. then examined titles and abstracts of the remaining publications against eligibility criteria. Following this initial screening, W.L.E.W. and D.S. evaluated the full texts of remaining articles for inclusion in this scoping review, with any doubts resolved upon discussion with all authors. Eligibility criteria were developed in consensus meetings between all authors, with a focus on broad criteria that would capture the maximum number of pertinent articles; original articles were included in this scoping review when they met the following criteria:

1. The relevant data were collected during the COVID-19 pandemic, pre-specified to include all studies after January 2020, to circumvent the varying timelines between countries.
2. The study was conducted in Europe. We defined Europe broadly as including all EU and EEA countries as well as those falling inside (not including contiguous transcontinental nations) the most commonly used boundaries [24]. The full list of countries comprises the following nations: Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czechia, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Iceland, Liechtenstein, Norway, Switzerland, United Kingdom, Ukraine, Belarus, Serbia (including Kosovo), Bosnia and Herzegovina, Moldova, Albania, North Macedonia, Montenegro, Andorra, San Marino, and Vatican City.
3. The study adopted either an interventional or observational design or was a relevant systematic review (with or without a meta-analysis). Non-systematic reviews, editorial or opinion articles, case reports, case series, and preclinical studies were excluded.
4. The study examined people with a diagnosis of MDD (full or sub-sample), established according to internationally recognised diagnostic criteria (e.g., ICD-10, DSM-5), which may have been recorded by a healthcare professional and/or rated using a structured or semi-structured diagnostic interview. This diagnosis had to be made at baseline or during the study assessment period.
5. The study examined working-age adults, as opposed to specific populations of young people (defined as under 18) or older people (defined loosely as aged over 65). This criterion was set due to variations in services for the young and elderly.
6. The study reported data pertaining to one or more of our pre-specified outcomes (relating to care pathways and continuity of care, as well as strategies for maintaining or improving care for people with MDD during COVID-19). These outcomes are detailed further in the below section entitled "Relevant outcomes".

No language restrictions were implemented during the searching and screening process, provided that the team were able to identify a native speaker of that language able and willing to translate the text. As this is a scoping review, the studies that passed eligibility criteria were not formally assessed for methodological quality.

Relevant outcomes

The outcome measures relevant to this scoping review relate broadly to several prespecified treatment gaps, and to mitigation

Table 1. Description of treatment gap outcomes that are pertinent to this scoping review

Pre-specified treatment gap	Brief description
Rates of undetected MDD	This gap comprises any outcome pertinent to missed diagnosis of MDD. Several factors may contribute to this missed detection, including help-seeking behaviour of patients, availability of various MDD services, and diagnostic accuracy of physicians.
Delays to detection or treatment of MDD	This gap comprises any outcome pertinent to delays in the detection or treatment of MDD. Examples of relevant data include reports of time elapsed between onset of a depressive episode and contact with care providers, or between onset and receiving treatment.
Rates of MDD treatment with pharmacological and nonpharmacological therapies	This gap comprises any outcome pertinent to the fraction of patients who receive (first-line) treatment for MDD. Our definition of treatment allows for both antidepressants and/or psychological therapy, as these are at the heart of modern standardised approaches to managing MDD.
Rates of follow-up contact for MDD	This gap comprises any outcome pertinent to care continuity and support for MDD. Examples of relevant data under this gap include the number of clinical contacts with a mental healthcare professional over a period of time and the nature of this contact (whether in-person, remote, or nonattended).
Access to secondary care or specialist services for MDD	This gap comprises any outcome pertinent to the use of specialist interventions in managing MDD. These specialist interventions encompass secondary or psychiatric care services and tertiary services. Examples of relevant data under this gap include the number of referrals and/or contacts within these specialist services (e.g., psychiatric services).

strategies for disruption to MDD care. The prespecified treatment gaps align with our previous European Brain Council Value of Treatment in MDD care pathways analysis [10], which evaluated treatment gaps prior to COVID-19. These treatment gap outcomes are described in more detail in Table 1. Mitigation strategies were relevant outcomes when trialled or implemented in any healthcare service setting to maintain or improve MDD care pathways disrupted during the pandemic. It was anticipated that these strategies would be primarily digital in nature, reflecting a shift in mental healthcare that was introduced even before the pandemic. Digital interventions broadly included any electronic methods that enabled service users with MDD to remain engaged with healthcare providers along care pathways, even without in-person interactions.

Data extraction and data synthesis

Data from included studies were extracted into a pre-designed Excel form. Data extracted included bibliographic information (such as authorship details and publication date), study characteristics (such as study design, location, and objectives), and summarised outcome data. The extracted data were summarised using tables and a narrative synthesis was constructed to analyse observed patterns and themes across the studies.

Results

Search and study selection

The electronic search of PubMed yielded 1084 records, while the search of PsycINFO via OVID yielded 660 records. An additional 12 studies were identified via hand searching of relevant reference lists. Following automated and manual duplicate removal, 1636 articles remained. Title and abstract screening of these articles removed 1470 articles, leaving 166 records for full-text screening. After evaluation of full texts, a further 155 articles were excluded, leaving 11 articles included in this scoping review. A flowchart of this search and screening process is presented in Figure 1.

Summary of eligible studies

Eleven articles were identified after eligibility screening spanned seven countries across Northern, Western, and Southern Europe: Italy,

United Kingdom, Germany, Spain, Denmark, France and the Netherlands. Nine of these studies were conducted in the period between March 2020 to May 2020, which corresponds to the introduction of nationwide restrictive measures (in many cases a lockdown) between March 9 and March 23 across the countries studied in this scoping review. Among the remaining two studies, one intersected with another period of lockdown in Italy [25], and the other immediately followed the loosening of restrictions in Denmark [26]. The timelines and pertinent restrictive measures for each study are summarised in Figure 2.

Impact of COVID-19 on treatment gaps in MDD care

Our scoping review search identified nine studies relevant to the aforementioned treatment gaps in MDD care (and two additional studies that were relevant to mitigation strategies), six of which investigated access to care. These studies are summarised in Table 2. Across these articles, there was a general tendency for a decrease in access to care during the COVID-19 pandemic: several studies reported changes in the number of clinical interactions relevant to MDD care, including number of psychiatric presentations to acute mental health assessment centres in London [27], number of admissions to emergency psychiatric care in Barcelona [28], number of hospitalisations to a psychiatric ward in Bologna [29], and number of referrals to inpatient and liaison psychiatry services in London [30]. There was consistency in the findings, with number of clinical interactions being reduced in all instances, to varying degrees. Olié and Dubois [31] further reported that 53.3% of participants with lifetime MDD did not have access to psychiatric care during the pandemic-mediated lockdown period in France. A study of general practitioner records in Germany reported that frequency of depressive disorder diagnoses was down by 11% in the second quarter of 2020, when the first lockdown was implemented, relative to the same period from 2017 to 2019, again indicative of the reduced access to care following the COVID-19 pandemic [32]. A cross-sectional survey study further found that people with depression were more likely to avoid primary care during the pandemic [33].

In addition, one study explored patients' perception on the effects of changing access to care: Kolbaek and Jepsen [26] reported that 12.4% of respondents with MDD in a Danish population cited reduced access to psychiatric treatment as a perceived reason for




Figure 1. PRISMA flow diagram for included studies.




Figure 2. Graphic highlighting the timeline of studies eligible for this scoping review and associated restrictive measures by country. Coloured shading represents lockdown period, grey shading represents study period.

Table 2: Summary of identified studies that investigate how the COVID-19 pandemic affected pre-specified treatment gaps in MDD care

Authors	Study location	Study design/type	Sample size	Mean age (years)	Sex (male: female)	Study objectives	Definition of MDD	Outcome(s) of relevance	Treatment gap findings
Splinter et al. 2021	Netherlands	Cross-sectional survey study	n = 5656	69.4	2390:3266	To identify: 1) the prevalence of healthcare avoidance, 2) which symptoms were left untreated, 3) determinants of healthcare avoidance behaviour, using self-reported measures and GP medical records.	Center for epidemiological studies depression Scale	Access to primary care: self-reported and GP-linked care avoidance (in population-based Rotterdam Study)	39.2% categorised as healthcare avoiders during the pandemic. Odds ratio for healthcare avoidance higher for people with vs without depression (per point increase in symptom score 1.13 [1.12 to 1.15]).
Mukadam et al. 2021	United Kingdom (London)	Retrospective interrupted time series	n = 2534	41.7	1204:1330	To describe the number/ types of emergency psychiatric presentations to 5 acute mental health assessment centres before/during COVID-19 and analyse changes in trends.	Clinician review of patient clinical notes	Access to care: number of psychiatric presentations and time-to help-seeking in acute mental health services	Absolute number of presentations for depressive symptoms fell: 134 pre-lockdown; 33 post-lockdown. Absolute number of presentations for suicidal ideation fell: 1033 pre-lockdown; 239 post-lockdown.
Amerio et al. 2021	Italy	Cross-sectional study	n = 6003	46.3*	2962:3041	To assess the impact of national lockdown measures on selected mental health outcomes, exploring its determinants and mediators.	2-item Patient Health Questionnaire	Treatment rates: change in use of antidepressants, relative to change in depressive symptoms (among a representative population sample)	N participants reporting depressive (PHQ-2 ≥ 3) symptoms during lockdown rose by 132% (14.3% to 33.2% of the total sample), whereas use of antidepressants increased only by 14% (3.6% to 4.1% of the total sample).
Olié et al. 2021	France	Cross-sectional survey study	n = 415	40.4 [†]	99:316	To identify predictors of psychological distress in the 1 st lockdown, to compare symptoms & lockdown habits between those with recent depressive episode and controls.	DSM-IV criteria for a depressive episode in last 2 years	Access to care: patient-reported access to secondary care in hospital psychiatric accident & emergency service	53.3% of lifetime MDD patients (n=184) had no psychiatric care and 7.2% (n=25) interrupted their usual medication schedule.
Bohlken et al. 2021	Germany	Cross-sectional study	n = 3,021,042	Not reported	Not reported	To outline changes in documented mental health diagnoses in German GP practices during COVID-19 vs 2017-2019 (average).	ICD-10 depression (F32, F33)	Access to care: number of depression diagnoses (based on GP and specialist medical record data)	Depression diagnosed less frequently (–11%) in the 2 nd quarter of 2020 (during the 1 st strict lockdown) vs 2017-2019 but diagnosed more frequently in the 3 rd (+3%) & 4 th quarter (9%) of 2020 vs 2017-2019.

Table 2 Continued

Authors	Study location	Study design/ type	Sample size	Mean age (years)	Sex (male: female)	Study objectives	Definition of MDD	Outcome(s) of relevance	Treatment gap findings
Panariello et al. 2021	Italy	Observational retrospective study	<i>n/a</i>	43.2	75:56	To investigate variation in psychiatric hospitalisation rates and clinical / socio-demographic differences between the first two waves of COVID-19, vs the same periods of the prior 3 years.	DSM-5 criteria for depression	Access to care: number of hospitalizations in a general hospital psychiatric ward	33.49% reduction in total psychiatric hospitalisation numbers during the first lockdown compared to the same period in the previous 3 years. In the second wave the number of MDD hospitalisations increased compared to the previous 3 years.
Kolbaek et al. 2021	Denmark	Cross-sectional survey study	n = 992	35.9 [†]	308:684	To evaluate COVID-19 lockdown effects on mental health of those with pre-existing mental illness, to determine factors associated with mental health deterioration.	ICD-10 diagnoses for depression (F32, F33)	Perceived access to care: patient-reported access to psychiatric treatment (in psychiatric hospitals)	12.4% of respondents with MDD cited reduced access to psychiatric treatment as a perceived reason for mental health deterioration.
Butler et al. 2021	United Kingdom	Retrospective inpatient e-referrals and records analysis	<i>n/a</i>	57.0	127:114	To characterise referrals made to inpatient liaison psychiatry services, compare findings with the same period in 2019, & characterise COVID-19-positive patients referred.	Clinician review of patient clinical notes	Access to care: number of referrals to inpatient liaison psychiatry service	The total number of referrals due to low mood decreased from 136 to 81.
Gomez-Ramiro et al., 2021	Spain	Retrospective records analysis	n = 1958	41.2	1018:940	To evaluate whether there were changes in the usage of emergency psychiatric services, before and after imposed lockdown in Barcelona.	ICD-10 diagnoses for depressive disorders (F32, F33, F34, F39)	Access to care: number of emergency psychiatric admissions in hospital psychiatric emergency service	The number of psychiatric emergency admissions with diagnoses of depressive disorders decreased from 74 (90 days before lockdown) to 43 (90 days during lockdown)

*Only information about the number of people in three age range categories (18-34, 35-54, and 55-74) were provided. Therefore, mean age was estimated using the the mid-point of each age range category.

[†]Only minimum, maximum, and median age, as well as sample size, were provided. Therefore, mean age was estimated using these parameters.

their mental health deterioration. The final identified study explored rates of treatment as an outcome, reporting that the use of antidepressants increased by 14% following the pandemic-induced lockdown, while the number of participants reporting depressive symptoms increased far more dramatically, by 132% [34]. No studies explored delays to the detection or treatment of depression, and there were no reports on the rates of follow-up contacts.

Mitigation strategies for COVID-19 disruptions to MDD care

Two included studies, summarised in Table 3, explored strategies implemented to mitigate COVID-19-related disruptions to MDD care. Both were longitudinal studies investigating digital interventions. Parolin et al. [25] aimed to explore the efficacy of a new smartphone app in Italy ("Italia Ti Ascolto"), which was introduced to manage several pandemic-related disruptions to mental health care, by offering several services including emotional distress management and linkage with mental health services. Overall user experience scored 88.98 (SD = 13.56) on the System Usability Scale [35], a usability scale ranging from 0 to 100, indicating a strong willingness among service users to shift towards digital interventions. However, there was no investigation of how the application affected care or psychopathological outcomes. Scholl et al. [36] investigated the feasibility of shifting service users from face-to-face group therapy to an online therapist-guided group chat programme in Germany. They found that there were no statistically significant differences in reported symptoms following the intervention, yet between 66 and 87% of participants in online group chats reported that they felt the intervention was good or excellent, suggesting some acceptability of this novel digital intervention following COVID-19. Several other digitally-enabled approaches to mental health management were identified during the initial search; for example, one report evaluated the utility of an application centred around mindfulness and psychotherapeutic support [37], while another reviewed mental health apps focused on evidence-based treatment in Australia [38]. These articles, however, did not meet our specific eligibility criteria pertinent to care pathways in Europe.

Discussion

Summary of results

The studies identified in this scoping review highlighted that the COVID-19 pandemic appeared to exacerbate some of our pre-specified treatment gaps, particularly during the first wave of COVID-19 across the Spring to Summer of 2020. Across the seven countries yielded in our search, restriction measures were enforced around approximately the same time, initially across March, then again across November to December in response to the second COVID-19 wave. All identified studies were conducted within a similar timeframe and either followed or intersected with the introduction of the initial restriction measures; however, the full nature of these restrictions did vary between countries. For instance, the United Kingdom and Italy differed in severity of at-home isolation orders, while the timing of lockdown policies between the United Kingdom and Germany differed [39]. There was nevertheless a common "lockdown" period of restricted contact shared across all countries in this review. Organisation of care, too, varied between countries, with the European Psychiatric Association reporting a significant difference in mental health service

Table 3: Summary of identified studies that investigated mitigation strategies for managing COVID-19-related disruptions to MDD care

Authors	Study location	Study design/type	Sample size	Mean age (years)	Sex (male: female)	Study objectives	Description of intervention	Definition of MDD	Findings of relevance
Parolin et al. 2021	Italy	Longitudinal study	n = 134	33.2	19:115	To present (preliminary) efficacy of a smartphone app designed to manage mental health issues, contain emotional distress, reduce pandemic preoccupation, and link affected individuals to local and national mental health services (the ITA app).	Digital mobile application: contains emotional distress, reduce pandemic preoccupation, and links individuals to local & national mental health services, guided by psychotherapists.	Depression anxiety stress scale-21	Assessment of app usability via the system usability scale revealed that overall user experience scored 88.98 (SD = 13.56) on System Usability Scale.
Scholl et al. 2021	Germany	Longitudinal feasibility study	n = 33	39.4	18:20	To assess the acceptability, usability, and feasibility of a group chat program in an outpatient psychiatric setting, designed to replace cancelled face-to-face group sessions.	Digital website: group chat sessions moderated by psychotherapists	Patient health questionnaire-9	No statistically significant difference in depressive symptoms pre- and post-intervention ($p = 0.93$). However, across sessions 66%-87% of participants indicated they thought the intervention was excellent/good.

delivery between countries during the first wave [40]. These differences pertained to variations in hospital-based care for mental health, to the creation of specialist units, and to the guidelines introduced by professional associations; all these factors are likely to affect (to some degree) our findings, though a full exploration of these disparities is beyond the scope. As this scoping review did not focus on capturing the full background context of government measures and care structures in each region, the trends we discuss below must therefore be interpreted with some degree of caution.

Investigations from the United Kingdom, Denmark, Spain, Italy, and France reported a reduction in access or perceived access to secondary or inpatient care, reflected in either reduced clinical contact or patient-reported decreases in clinical access [26–31]. Studies of primary care services also indicated a reduction in general practitioner visits for depression in the Netherlands and Germany during the pandemic, compared to pre-pandemic rates [32, 33]. A single study assessing rates of self-reported pharmacological treatment for MDD [34], found a substantial increase in reported depressive symptoms that was not commensurate with a more modest increase in antidepressant usage. This discrepancy could imply a reduction in the proportion of patients receiving antidepressants during the pandemic. Although this evidence is patient-reported and indirect, it is supported by a study in the United Kingdom, which highlighted that rates of increasing antidepressant prescriptions in 2020 were not significantly different from pre-pandemic trends [41]. These results are consistent with other reports that underscore how COVID-19 has decreased overall healthcare utilisation, a phenomenon that can be explained by the restrictions imposed by pandemic-induced lockdowns, fear of exposure to the virus, and inadequate availability of healthcare resources, amongst others [15, 42].

We were cognisant to enforce relatively loose inclusion criteria for the definition of MDD in this review, given the limited available data addressing our treatment gaps. Despite this, only nine pertinent studies were identified, and only a few of the pre-specified treatment gaps were addressed across these reports. While some trends were evident in this scoping review, these cannot be interpreted with certainty, as there is heterogeneity among the outcomes evaluated across studies. Several of the studies employed patient-reported data to draw conclusions about the effect of the pandemic, but this only acts as a proxy for actual changes in relevant outcomes, with the accuracy of self-reported data varying heavily [43, 44]. Moreover, several investigations were conducted at a very small number of clinical sites, such that the absolute numbers assessed were often very small; it is thus difficult to aver the generalisability of these conclusions. Rates of undetected MDD could only be crudely assessed by evaluating the number of positive diagnoses during the pandemic, while no identified articles explored follow-up contacts for MDD and delays to the detection of MDD as outcomes.

It is important to note that there were a number of studies identified in our systematic search that did not meet our inclusion criteria, but that did have relevant insights to support some of the findings. Several articles focused on treatment gaps broadly across psychiatric care rather than specifically for MDD. For instance, Sampson and Wright [45] found a decrease in referrals to psychiatric liaison services across North Central London during the first pandemic wave, while Pignon and Gourevitch [46] reported reduced emergency psychiatric consultations during the first 4 weeks of lockdown in Paris and its suburbs. A cross-sectional study in Austria further reported a decrease in the percentage of participants that self-reported treatment for broad mental

disorders during lockdown [47]. While not specific to MDD, these findings altogether corroborate the notion of reduced access to acute care, secondary care or rates of treatment in MDD management during the pandemic. Rates of broader psychiatric treatment were also peripherally assessed in several articles: in a survey of university students in France, Wathet and Duhem [48] reported that 6.8% were seeing a professional for mental health reasons, far less than the 16.1% that were assessed with MDD based on the Beck Depression Inventory. Across three Dutch case-control cohorts, Pan and Kok [49] reported that only 55% of participants with a lifetime mental health condition were undergoing treatment during the pandemic. While these investigations for the rate of treatment are further suggestive of impaired healthcare provision for psychiatric conditions and thus MDD, these statistics were not compared to pre-pandemic statistics, such that direct comparison of treatment rates for MDD was not possible.

There were also a large number of articles that did not explore our outcomes of interest but did directly assess changes in MDD prevalence during COVID-19, generally highlighting increased prevalence in depressive disorders following the pandemic [50–53]. This relationship has been further underscored in several comprehensive systematic reviews, which suggest worsened levels of overall psychological distress during COVID-19 [19, 54]. This was concomitant with a greater need for therapeutic support and heightened public concern about treatment impairment [55]. Given the COVID-19-mediated impairment of MDD care provision identified in this review, this is a particularly serious public health concern. Altogether, this evidence emphasises the need to ameliorate these worsened treatment gaps and make MDD care more resilient to external factors.

To this end, we also attempted to collate evidence of mitigation strategies introduced during the pandemic to improve MDD care. However, given our inclusion criteria, only two studies were included in our synthesis [25, 36]; both these studies trialled digital interventions, one to replace face-to-face group therapy sessions and the other to link service users with mental health services, indicating that participants were receptive to the usage of these tools, though their efficacy in managing MDD is unclear. Once again, our search did identify a number of other studies exploring digital interventions, but that did not strictly assess an outcome of interest or was too broad in nature. For instance, Bauerle and Jahre [37] evaluated an e-mental health intervention integrating mindfulness and cognitive behavioural therapy, highlighting some therapeutic efficacy without addressing implications on care provision. Olwill and Mc Nally [56] surveyed psychiatrists about their experiences with phone consultations, but this was for broader mental health concerns. While these articles did not meet our inclusion criteria, they nonetheless illustrate how the pandemic has expedited a shift into digital or remote solutions for mental health care more generally, a trend likely to continue in the post-pandemic era given the reported efficacy of such solutions even in non-pandemic contexts [57, 58]. Clearly, more work needs to be done to identify how these innovations have affected, and continue to affect, MDD care during COVID-19. Our search strategy failed to identify articles that offered detailed evaluations on how remote care and the use of teleconsultations during COVID-19 affected MDD service provision in particular, though there was evidence for increased telemedicine usage across mental health [59, 60]; to this end, it would be useful to have more detailed evaluations on how the general shift to teleconsultations across healthcare has affected specific MDD care pathways.

In addition to the aforementioned mitigation strategies, it is important to consider the extent to which restructuring of mental health care services addressed COVID-19-mediated gaps in psychiatric care provision. This re-organisation of care arose due to a need to divert people away from acute hospitals (to reduce contact and relieve hospital burden) while maintaining some level of support for individuals suffering from mental health conditions. While our search strategy did not yield MDD-specific reports on this topic, several reports highlight how community mental health services across the world continued to provide broad psychiatric care and support throughout the pandemic, despite the many challenges they faced [61–63]. Furthermore, it is clear that these community services adopted digital technologies and telemedicine to ensure care delivery in a safe and optimal manner [64, 65], with relatively favourable perceptions of this digital shift, which may have long-term implications for the how community mental health resolves to bridge the gaps in MDD, and psychiatric, care provision.

Strengths and limitations

There were several strengths to this scoping review. This study is the first to broadly investigate the effects of COVID-19 on pre-existing treatment gaps, and more broadly care provision, specific to MDD in Europe. Moreover, we conducted this review in accordance with rigorous PRISMA-ScR guidelines and adopted a systematic approach to our search and screening methodology, to ensure we properly synthesised evidence on this topic. We further registered a protocol prior to the conduct of this study, adhering to it to achieve objectivity and transparency in our review. Our eligibility criteria were also meticulously developed in several consensus meetings to ensure the review was comprehensive while relevant to MDD care provision, and we permitted studies that were not written in English for better coverage, though this did not facilitate the inclusion of additional studies.

Limitations of this study include the lack of critical appraisal for study quality and the broad nature of the data synthesis, though these limitations are a staple in scoping reviews. The eligibility criteria adopted in this review are concomitant with several other limitations: our MDD criteria were relatively loose to maximise scope, and certain subgroups were not investigated at length (e.g., the older adult population). Despite some methodological leniency, there were only a small number of articles eligible for analysis following our rigorous screening, which limits the interpretation of our findings. There are limitations to the generalisability of our findings across continental Europe, given the small number of countries reported on in this review, primarily concentrated across Northern, Western, and Southern Europe. Certain treatment gaps were left completely unaddressed, meaning we do not have a complete picture of how COVID-19 has affected MDD care provision in Europe. Furthermore, there was much methodological heterogeneity across studies and therefore a lack of standardisation, limiting the types of analysis that could be conducted with the results. We also acknowledge the possibility of missed relevant articles because of delays in indexing and because this is a fast-moving field. A final important limitation of this scoping review is the difficulty in directly comparing the extent of treatment gaps and mitigation strategies during the pre- and peri-pandemic periods. For example, while Butler and Delvi [30] found a 40.4% decrease in number of people accessing secondary care from 2019 to 2020, we cannot estimate comparable rates for the continued or post-pandemic period, rendering it difficult to assess the complete role of COVID-19 in moderating this particular treatment gap.

Future directions

In the peri- and post-pandemic era, it will be important to collate and re-evaluate several of the outcomes from the studies identified in this scoping review. There is a need to analyse longer-term observational data from MDD care services and wider public samples, in order to determine the nature and extent of treatment gaps in MDD care, particularly during the latter stages of and gradual transition from the pandemic. A fully developed understanding of how the pandemic impacted MDD care provision in Europe would enable comparison with the implementation of recommended guidelines, and importantly enable us to capture the effects of both positive (for instance, via the implementation of guideline recommendations) and negative events (like the pandemic) on MDD care.

This scoping review also highlighted several additional studies that could be conducted to help develop a full perspective on the impacts of COVID-19 on MDD care in Europe. There is still much scope to investigate the digital mitigation strategies implemented for management of MDD during the pandemic. The use of digital strategies in MDD has been a topic of interest even prior to the pandemic, with a large variety of tools deployed with mixed efficacy. For instance, evidence for internet-based cognitive behavioural therapy is fairly mature [66], though the efficacy of other innovations, such as virtual reality, chatbots, and smartphone applications, has yet to be fully validated [58] and requires more study. Telepsychiatry too has grown extensively in popularity during the pandemic, though there is still scope for refinement of its implementation [67]. Our search found that many such digital interventions have been trialled and implemented during the pandemic; however, many investigations to date did not meet our inclusion criteria due to a lack of specificity for MDD service provision. This lack of specificity was a common occurrence for articles that did not pass screening for our eligibility criteria; while understandable given the comorbidity of MDD with other mental health disorders, it will be important to conduct additional investigations specific to MDD care, as treatment pathways in this subgroup already contain complexities. During our initial search, there were also several pertinent articles for specific subgroups (such as student populations) that did not meet eligibility criteria – it would thus be useful to conduct a similar review surveying MDD care pathways in these subgroup populations. For example, an investigation into how COVID-19 affected MDD care provision in the elderly population would be interesting, as they were likely impacted in different manners, due to various subgroup-specific factors, including the presence of comorbidities and differing access or skills with digitally enabled solutions that were trialled in the pandemic. Several of our pre-specified treatment gaps – especially delays to MDD detection and rates of follow-up – were not fully addressed by the current literature, further reinforcing that additional retrospective analysis would be useful. While there were longitudinal investigations, none included sufficient follow-up to enable a complete evaluation of COVID-19-related trends.

Despite the uncertainty around many of the conclusions from this scoping review, stemming from a limited amount of available data, treatment gaps for MDD appeared to be exacerbated by COVID-19. It will therefore be important to re-evaluate previous recommendations for MDD care to ensure they are robust in the face of unpredictable events. Treatment gaps in MDD care clearly remain extensive and problematic, so it is more critical than ever to implement standardised solutions throughout the pathway.

Acknowledgements. The authors acknowledge the assistance and support from all members of the European Brain Council Value of Treatment Research Working Groups (particularly the MDD group). We are grateful to Dr. Fabio Panariello, who kindly provided us with additional data that was key in this manuscript. We also acknowledge the contributions of Dr. Mutahira Qureshi, who offered advice and translation support while this research was conducted.

Financial support. This work was supported by the European Brain Council (EBC). This work is also supported by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London.

Competing interest. R.S. has received honoraria from Janssen. A.H.Y. has been commissioned to provide lectures and advice to all major pharmaceutical companies with drugs used in affective and related disorders; has also undertaken investigator-initiated studies funded by Astra Zeneca, Eli Lilly, Lundbeck, and Wyeth. V.Q. is employed at the European Brain Council (funder) and P.B. undertakes work for the European Brain Council. D.H.M. has received CME-related honoraria and served as a consultant for Abbott, Angelini, Ethypharm Digital Therapy, and Janssen-Cilag with no financial or other relationship relevant to the subject of this article. J.S. has received EBC academic expert honoraria with no financial or other relationship relevant to the subject of this article. W.L.E.W. and D.S. declare no competing interests.

References

- [1] World Health Organization. Depression and Other Common Mental Disorders: Global Health Estimates. Geneva; 2017.
- [2] Gabriel FC, de Melo DO, Fraguas R, Leite-Santos NC, Mantovani da Silva RA, Ribeiro E. Pharmacological treatment of depression: A systematic review comparing clinical practice guideline recommendations. *PLoS One*. 2020;15(4):e0231700.
- [3] Gautam S, Jain A, Gautam M, Vahia VN, Grover S. Clinical practice guidelines for the management of depression. *Indian J Psychiatry*. 2017; 59(Suppl 1):S34–50.
- [4] Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: The National Comorbidity Survey. *Am J Psychiatry*. 1994;151(7):979–86.
- [5] Goldberg D. The heterogeneity of "major depression". *World Psychiatry*. 2011;10(3):226–8.
- [6] Menard C, Hodes GE, Russo SJ. Pathogenesis of depression: Insights from human and rodent studies. *Neuroscience*. 2016;321:138–62.
- [7] Almeida SS, Zizzi FB, Cattaneo A, Comandini A, Di Dato G, Lubrano E, et al. Management and treatment of patients with major depressive disorder and chronic diseases: A multidisciplinary approach. *Front Psychol*. 2020;11:542444.
- [8] Edwards G, Nuckols T, Herrera N, Danovitch I, Ishak WW. Improving depression Management in Patients with medical illness using collaborative care: Linking treatment from the inpatient to the outpatient setting. *Innov Clin Neurosci*. 2019;16(11–12):19–24.
- [9] Unutzer J, Park M. Strategies to improve the management of depression in primary care. *Prim Care*. 2012;39(2):415–31.
- [10] Strawbridge R, McCrone P, Ulrichsen A, Zahn R, Eberhard J, Wasserman D, et al. Care pathways for people with major depressive disorder: A European Brain Council Value of Treatment study. *Eur Psychiatry*. 2022;1–21.
- [11] Hidaka BH. Depression as a disease of modernity: Explanations for increasing prevalence. *J Affect Disord*. 2012;140(3):205–14.
- [12] Nutting PA, Rost K, Dickinson M, Werner JJ, Dickinson P, Smith JL, et al. Barriers to initiating depression treatment in primary care practice. *J Gen Intern Med*. 2002;17(2):103–11.
- [13] Wainberg ML, Scorza P, Shultz JM, Helpman L, Mootz JJ, Johnson KA, et al. Challenges and opportunities in global mental health: A research-to-practice perspective. *Curr Psychiatry Rep*. 2017;19(5):28.
- [14] Kendzerska T, Zhu DT, Gershon AS, Edwards JD, Peixoto C, Robillard R, et al. The effects of the health system response to the COVID-19 pandemic on chronic disease management: A narrative review. *Risk Manag Healthc Policy*. 2021;14:575–84.
- [15] Moynihan R, Sanders S, Michaleff ZA, Scott AM, Clark J, To EJ, et al. Impact of COVID-19 pandemic on utilisation of healthcare services: A systematic review. *BMJ Open*. 2021;11(3):e045343.
- [16] Weaver N, Coffey M, Hewitt J. Concepts, models and measurement of continuity of care in mental health services: A systematic appraisal of the literature. *J Psychiatr Ment Health Nurs*. 2017;24(6):431–50.
- [17] Wiktorowicz ME, Di Pierdomenico K, Buckley NJ, Lurie S, Czukur G. Governance of mental healthcare: Fragmented accountability. *Soc Sci Med*. 2020;256:113007.
- [18] Mishra V, Seyedzenouzi G, Almohtadi A, Chowdhury T, Khashkhusha A, Axiq A, et al. Health inequalities during COVID-19 and their effects on morbidity and mortality. *J Healthc Leadersh*. 2021;13:19–26.
- [19] Xiong J, Lipsitz O, Nasri F, Lui LMW, Gill H, Phan L, et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. *J Affect Disord*. 2020;277:55–64.
- [20] Lal A, Erondur NA, Heymann DL, Gitahi G, Yates R. Fragmented health systems in COVID-19: Rectifying the misalignment between global health security and universal health coverage. *Lancet*. 2021;397(10268):61–7.
- [21] Nimako K, Kruk ME. Seizing the moment to rethink health systems. *Lancet Glob Health*. 2021;9(12):e1758–e62.
- [22] Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): Checklist and explanation. *Ann Intern Med*. 2018;169(7):467–73.
- [23] Sually D, Wong WLE, Hidalgo-Mazzei D, Quoidbach V, Simon J, Boyer P, et al. The effects of COVID-19 on European healthcare provision for people with major depressive disorder: a scoping review protocol. *medRxiv*. 2022:2022.02.17.22269638.
- [24] WorldAtlas. Map and Details of all 7 Continents 2023. Available from: <https://www.worldatlas.com/continents>.
- [25] Parolin LAL, Benzi IMA, Fanti E, Milesi A, Cipresso P, Preti E. Italia Ti Ascolto [Italy, I am listening]: An app-based group psychological intervention during the COVID-19 pandemic. *Res Psychother*. 2021;24(1):517.
- [26] Kolbaek P, Jepsen OH, Speed M, Ostergaard SD. Mental health of patients with mental illness during the COVID-19 pandemic lockdown: A questionnaire-based survey weighted for attrition. *Nord J Psychiatry*. 2022;76(5):338–47.
- [27] Mukadam N, Sommerlad A, Wright J, Smith A, Szczap A, Solomou S, et al. Acute mental health presentations before and during the COVID-19 pandemic. *BJPsych Open*. 2021;7(4):e134.
- [28] Gomez-Ramiro M, Fico G, Anmella G, Vazquez M, Sague-Vilavella M, Hidalgo-Mazzei D, et al. Changing trends in psychiatric emergency service admissions during the COVID-19 outbreak: Report from a worldwide epicentre. *J Affect Disord*. 2021;282:26–32.
- [29] Panariello F, Longobardi S, Cellini L, De Ronchi D, Atti AR. Psychiatric hospitalization during the two SARS-CoV-2 pandemic waves: New warnings for acute psychotic episodes and suicidal behaviors. *World J Psychiatry*. 2021;11(11):1095–105.
- [30] Butler M, Delvi A, Mujic F, Broad S, Pauli L, Pollak TA, et al. Reduced activity in an inpatient liaison psychiatry service during the first wave of the COVID-19 pandemic: Comparison with 2019 data and characterization of the SARS-CoV-2 positive cohort. *Front Psych*. 2021;12:619550.
- [31] Olié E, Dubois J, Benramdane M, Guillaume S, Courtet P. Psychological state of a sample of patients with mood disorders during the first French COVID-19 lockdown. *Sci Rep*. 2021;11(1):23711.
- [32] Bohlken J, Kostev K, Riedel-Heller S, Hoffmann W, Michalowsky B. Effect of the COVID-19 pandemic on stress, anxiety, and depressive disorders in German primary care: A cross-sectional study. *J Psychiatr Res*. 2021;143: 43–9.
- [33] Splinter MJ, Velek P, Ikram MK, Kieboom BCT, Peeters RP, Bindels PJE, et al. Prevalence and determinants of healthcare avoidance during the COVID-19 pandemic: A population-based cross-sectional study. *PLoS Med*. 2021;18(11):e1003854.
- [34] Amerio A, Lugo A, Stival C, Fanucchi T, Gorini G, Pacifici R, et al. COVID-19 lockdown impact on mental health in a large representative sample of Italian adults. *J Affect Disord*. 2021;292:398–404.

- [35] Brooke J. SUS: A quick and dirty usability scale. *Usability Eval Ind.* 1995;189.
- [36] Scholl J, Kohls E, Gorges F, Steinbrecher M, Baldofski S, Moessner M, et al. Acceptability and feasibility of the transfer of face-to-face group therapy to online group chats in a psychiatric outpatient setting during the COVID-19 pandemic: Longitudinal observational study. *JMIR Form Res.* 2021; 5(7):e27865.
- [37] Bauerle A, Jahre L, Teufel M, Jansen C, Musche V, Schweda A, et al. Evaluation of the E-mental health mindfulness-based and skills-based “CoPE it” intervention to reduce psychological distress in times of COVID-19: Results of a Bicentre longitudinal study. *Front Psych.* 2021;12:768132.
- [38] Marshall JM, Dunstan DA, Bartik W. Smartphone psychological therapy during COVID-19: A study on the effectiveness of five popular mental health apps for anxiety and depression. *Front Psychol.* 2021;12:775775.
- [39] Meintrup D, Nowak-Machen M, Borgmann S. A comparison of Germany and the United Kingdom indicates that more SARS-CoV-2 circulation and less restrictions in the warm season might reduce overall COVID-19 burden. *Life (Basel).* 2022;12(7).
- [40] Rojnic Kuzman M, Vahip S, Fiorillo A, Beezhold J, Pinto da Costa M, Skugarevsky O, et al. Mental health services during the first wave of the COVID-19 pandemic in Europe: Results from the EPA ambassadors survey and implications for clinical practice. *Eur Psychiatry.* 2021;64(1):e41.
- [41] Rabeea SA, Merchant HA, Khan MU, Kow CS, Hasan SS. Surging trends in prescriptions and costs of antidepressants in England amid COVID-19. *Daru.* 2021;29(1):217–21.
- [42] Nunez A, Sreenganga SD, Ramaprasad A. Access to healthcare during COVID-19. *Int J Environ Res Public Health.* 2021;18(6).
- [43] Hafferty JD, Campbell AI, Navrady LB, Adams MJ, MacIntyre D, Lawrie SM, et al. Self-reported medication use validated through record linkage to national prescribing data. *J Clin Epidemiol.* 2018;94:132–42.
- [44] Short ME, Goetzel RZ, Pei X, Tabrizi MJ, Ozminkowski RJ, Gibson TB, et al. How accurate are self-reports? Analysis of self-reported health care utilization and absence when compared with administrative data. *J Occup Environ Med.* 2009;51(7):786–96.
- [45] Sampson EL, Wright J, Dove J, Mukadam N. Psychiatric liaison service referral patterns during the UK COVID-19 pandemic: An observational study. *Eur J Psychiatry.* 2022;36(1):35–42.
- [46] Pignon B, Gourevitch R, Tebeka S, Dubertret C, Cardot H, Dauriac-Le Masson V, et al. Dramatic reduction of psychiatric emergency consultations during lockdown linked to COVID-19 in Paris and suburbs. *Psychiatry Clin Neurosci.* 2020;74(10):557–9.
- [47] Simon J, Helter TM, White RG, van der Boor C, Laszewska A. Impacts of the Covid-19 lockdown and relevant vulnerabilities on capability well-being, mental health and social support: An Austrian survey study. *BMC Public Health.* 2021;21(1):314.
- [48] Wathélet M, Duhem S, Vaiva G, Baubet T, Habran E, Veerapa E, et al. Factors associated with mental health disorders among university students in France confined during the COVID-19 pandemic. *JAMA Netw Open.* 2020;3(10):e2025591.
- [49] Pan K-Y, Kok AAL, Eikelenboom M, Horsfall M, Jorg F, Luteijn RA, et al. The mental health impact of the COVID-19 pandemic on people with and without depressive, anxiety, or obsessive-compulsive disorders: A longitudinal study of three Dutch case-control cohorts. *Lancet Psychiatry.* 2021; 8(2):121–9.
- [50] Babicki M, Kowalski K, Bogudzinska B, Mastalerz-Migas A. Impact of the COVID-19 pandemic on mental well-being. A Nationwide online survey covering three pandemic waves in Poland. *Front Psych.* 2021;12:804123.
- [51] Parlapani E, Holeva V, Voitsidis P, Blekas A, Gliatas I, Porfyri GN, et al. Psychological and behavioral responses to the COVID-19 pandemic in Greece. *Front Psych.* 2020;11:821.
- [52] Sonderskov KM, Dinesen PT, Santini ZI, Ostergaard SD. The depressive state of Denmark during the COVID-19 pandemic. *Acta Neuropsychiatr.* 2020;32(4):226–8.
- [53] Winkler P, Formanek T, Mlada K, Kagstrom A, Mohrova Z, Mohr P, et al. Increase in prevalence of current mental disorders in the context of COVID-19: Analysis of repeated nationwide cross-sectional surveys. *Epidemiol Psychiatr Sci.* 2020;29:e173.
- [54] COVID-19 Mental Disorders Collaborators. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic. *Lancet.* 2021;398(10312):1700–12.
- [55] Favreau M, Hillert A, Osen B, Gartner T, Hunatschek S, Riese M, et al. Psychological consequences and differential impact of the COVID-19 pandemic in patients with mental disorders. *Psychiatry Res.* 2021;302: 114045.
- [56] Olwill C, Mc Nally D, Douglas L. Psychiatrist experience of remote consultations by telephone in an outpatient psychiatric department during the COVID-19 pandemic. *Ir J Psychol Med.* 2021;38(2):132–9.
- [57] Moshe I, Terhorst Y, Philippi P, Domhardt M, Cuijpers P, Cristea I, et al. Digital interventions for the treatment of depression: A meta-analytic review. *Psychol Bull.* 2021;147(8):749–86.
- [58] Torous J, Bucci S, Bell IH, Kessing LV, Faurholt-Jepsen M, Whelan P, et al. The growing field of digital psychiatry: Current evidence and the future of apps, social media, chatbots, and virtual reality. *World Psychiatry.* 2021; 20(3):318–35.
- [59] Abraham A, Jithesh A, Doraiswamy S, Al-Khawaga N, Mamtani R, Cheema S. Telemental health use in the COVID-19 pandemic: A scoping review and evidence gap mapping. *Front Psych.* 2021;12:748069.
- [60] Patel R, Irving J, Brinn A, Broadbent M, Shetty H, Pritchard M, et al. Impact of the COVID-19 pandemic on remote mental healthcare and prescribing in psychiatry: An electronic health record study. *BMJ Open.* 2021;11(3):e046365.
- [61] Kopelovich SL, Monroe-DeVita M, Buck BE, Brenner C, Moser L, Jarskog LF, et al. Community mental health care delivery during the COVID-19 pandemic: Practical strategies for improving Care for People with serious mental illness. *Community Ment Health J.* 2021;57(3):405–15.
- [62] Lestari R, Setyawan FEB. Mental health policy: Protecting community mental health during the COVID-19 pandemic. *J Public Health Res.* 2021; 10(2).
- [63] Vigo D, Patten S, Pajer K, Krausz M, Taylor S, Rush B, et al. Mental health of communities during the COVID-19 pandemic. *Can J Psychiatr.* 2020; 65(10):681–7.
- [64] Burton L, Wall A, Perkins E. Making it work: The experiences of delivering a community mental health service during the COVID-19 pandemic. *Int J Environ Res Public Health.* 2022;19(19).
- [65] Sklar M, Reeder K, Carandang K, Ehrhart MG, Aarons GA. An observational study of the impact of COVID-19 and the rapid implementation of telehealth on community mental health center providers. *Implement Sci Commun.* 2021;2(1):29.
- [66] Karyotaki E, Efthimiou O, Miguel C, Bermpohl FMG, Furukawa TA, Cuijpers P, et al. Internet-based cognitive behavioral therapy for depression: A systematic review and individual patient data network meta-analysis. *JAMA Psychiatry.* 2021;78(4):361–71.
- [67] Greenhalgh T, Wherton J. Telepsychiatry: learning from the pandemic. *Br J Psychiatry.* 2022:1–5.